AstraZeneca is committed to discovering and developing compounds that improve patient care in neuroscience.
With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders.
Our focus on unmet medical needs
More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.
Alzheimer's disease (AD)
AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.
Opioid-induced constipation (OIC)
OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.
What we're working on
We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.
Lanabecestat is an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III development as a potential treatment for early Alzheimer’s disease. Lanabecestat has been shown in studies to reduce levels of amyloid beta in the cerebrospinal fluid of people with Alzheimer’s and healthy volunteers. The progression of Alzheimer’s disease is characterised by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of amyloid beta. Inhibiting BACE is expected to prevent the formation and build-up of amyloid plaque which in turn may help slow the progression of the disease.
MEDI1814 is a monoclonal antibody currently in Phase I development as a potential disease-modifying treatment for Alzheimer’s disease (AD). MEDI1814 is the first antibody to selectively target amyloid-beta 42, a form of amyloid which is particularly associated with AD. The build-up of plaque in the brain containing the peptide amyloid-beta is one of the key characteristics of AD. Early trials have shown that MEDI1814 can reduce levels of this more toxic form of amyloid-beta in Alzheimer’s disease patients.
AstraZeneca and Lily are co-developing MEDI1814 as part of the BACE alliance.
Image: Artistic rendering of BACE enzyme.
Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers
Opportunities for collaboration
Our approach in Neuroscience looks to maximise revenue through externalisation and on-market products; advance the novel product pipeline with partnerships where appropriate; and preserve a company stake in the most promising assets.
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Veeva ID: Z4-3582
Date of next review: March 2018